Paclitaxel is one of the commonly used drugs in postoperative chemotherapy for ovarian cancer patients. However, affected by drug dosage and individual differences in the course of medication, patients will have different degrees of adverse reactions, which will cause damage to the patient’s body once they occur. This paper retrospectively analyzed the clinical data of patients with severe allergic reactions such as fecal incontinence and numbness of hands and feet caused by the use of paclitaxel liposome during postoperative chemotherapy in a case of ovarian cancer admitted to our hospital. The causes and corresponding treatment measures were analyzed, in order to provide the reference for medical staff to take effective countermeasures in advance in the future.
References
[1]
Chen, J., Wei, Z., Fu, K., Duan, Y., Zhang, M., Li, K., et al. (2022) Non-Apoptotic Cell Death in Ovarian Cancer: Treatment, Resistance and Prognosis. Biomedicine & Pharmacotherapy, 150, Article 112929. https://doi.org/10.1016/j.biopha.2022.112929
[2]
Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., et al. (2020) ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer. Annals of Oncology, 31, 1606-1622. https://doi.org/10.1016/j.annonc.2020.08.2102
[3]
Na, L. and Liu, J. (2022) Analysis of Adverse Reactions and Rational Drug Use of Paclitaxel. Chinese Journal of Practical Medicine, 17, 184-186.
[4]
Jia, Y., Zhang, Q., Cui, C., Jia, Y., Zhang, X., et al. (2019) Clinical Effect of Paclitaxel Combined with Carboplatin in Adjuvant Chemotherapy for Triple-Negative Breast Cancer. Clinical Research, 31, 22-25.
[5]
Zhang, X., Fu, Y., Tian, Y., et al. (2023) Influencing Factors of CINV after Paclitaxel Combined with Carboplatin Chemotherapy in Elderly Gynecological Tumor Patients. Chinese Journal of Gerontology, 43, 1316-1319.
[6]
Zhang, W., Shi, Y., Chen, Y., Yu, S., Hao, J., Luo, J., et al. (2010) Enhanced Antitumor Efficacy by Paclitaxel-Loaded Pluronic P123/F127 Mixed Micelles against Non-Small Cell Lung Cancer Based on Passive Tumor Targeting and Modulation of Drug Resistance. European Journal of Pharmaceutics and Biopharmaceutics, 75, 341-353. https://doi.org/10.1016/j.ejpb.2010.04.017
[7]
Chou, P., Huang, Y., Cheng, M., Rau, K. and Fang, Y. (2020) Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis. International Journal of Nanomedicine, 15, 1731-1743. https://doi.org/10.2147/ijn.s231407
[8]
Chen, Q., Zhang, Q., Liu, J., et al. (2003) Paclitaxel Liposomes versus Conventional Paclitaxel in the Treatment of Breast Cancer and Non-Small Cell Lung Cancer. Chinese Journal of Oncology, No. 2, 88-90.
[9]
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K.F., et al. (1997) Limited Oral Bioavailability and Active Epithelial Excretion of Paclitaxel (Taxol) Caused by P-Glycoprotein in the Intestine. Proceedings of the National Academy of Sciences, 94, 2031-2035. https://doi.org/10.1073/pnas.94.5.2031
[10]
Li, Y.R., Zhang, S.T., Bao, Z., et al. (2023) Analysis of Adverse Reactions of 4 Paclitaxel Antitumor Drugs Based on Open FDA Database. Guangxi Medical Journal, 45, 1735-1739.
[11]
Kong, L., Liu, X.E. and Wei, T. (2006) 1 Case of Acute Severe Allergic Reaction Induced by Paclitaxel. Shandong Medical Journal, No. 5, 16.
[12]
Xin, W., Huang, P., Lu, X., et al. (2019) Guidance on Hypersensitivity Pre-Treatment of Paclitaxel Preparations. Chinese Journal of Modern Applied Pharmacy, 36, 1023-1027.
[13]
Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G. and Belinson, J. (2000) Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center. Journal of Clinical Oncology, 18, 102-102. https://doi.org/10.1200/jco.2000.18.1.102
[14]
Banerji, A., Lax, T., Guyer, A., Hurwitz, S., Camargo, C.A. and Long, A.A. (2014) Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review. The Journal of Allergy and Clinical Immunology: In Practice, 2, 428-433. https://doi.org/10.1016/j.jaip.2014.04.010
[15]
Ling, X. (2019) Analysis of Adverse Reactions and Clinical Rational Use of Paclitaxel. Journal of Integrative Chinese and Western Medicine Cardiovascular Diseases Electronic, 8, 60-61.
[16]
Chen, X. and Lan, X. (2019) Effect of Nutrition Support Combined with Stage Nursing on Patients with Drug Poisoning by Hemoperfusion. Medical Equipment, 37, 99-102.
